MedTrace Logo

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

NCT03820141 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-04-20

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.

Conditions

Interventions

DRUG

Durvalumab

programmed cell death-ligand 1 inhibitor

DRUG

Trastuzumab

anti-HER2 monoclonal antibody

DRUG

Pertuzumab

anti-HER2 monoclonal antibody

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • The Methodist Hospital Research Institute

    lead OTHER

Principal Investigators

  • Polly Niravath, M.D. · Houston Methodist Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2024-10-30
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03820141 on ClinicalTrials.gov